Drugs / BECOTATUG
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05164848 | Dec 2021 → Oct 2023 | esophageal squamous cell carcinoma | Peking University | Unknown | No outcome recorded |
| Phase 1 | NCT04448379 | Jun 2020 → Dec 2021 | non-small cell lung carcinoma | Shanghai JMT-Bio Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT04689100 | Apr 2017 → Dec 2021 | neoplasm | Shanghai JMT-Bio Inc. | Unknown | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06989671 | Aug 2025 → Dec 2027 expected | head and neck squamous cell carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06892431 | Apr → Dec 2025 overdue | nasopharyngeal carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06089330 | Jan → Jul 2024 | colorectal cancer | Shanghai JMT-Bio Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT06391944 | Nov 2021 → May 2023 overdue | non-small cell lung carcinoma | Shanghai JMT-Bio Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05132777 | Nov 2021 → Sep 2023 | non-small cell lung carcinoma | Shanghai JMT-Bio Inc. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06319313 | May 2024 → Jul 2026 overdue | non-small cell squamous lung carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07134205 | Oct 2025 → Jun 2027 expected | colorectal cancer | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06735391 | Oct 2024 → Sep 2026 overdue | — | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06380348 | Apr 2024 → Mar 2027 expected | non-small cell lung carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-09-24 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Results VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF BECOTATUG (JMT101) IN COMBINATION WITH OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NSCLC HARBOURING EGFR EXON 20 INSERTION MUTATIONS ACHIEVES POSITIVE TOPLINE RESULTS irasia.com ↗ |
| 2025-06-02 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - JMT101 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF COLORECTAL CANCER irasia.com ↗
JMT101 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF COLORECTAL CANCER |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-24 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF BECOTATUG (JMT101) IN COMBINATION WITH OSIMERTINIB FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NSCLC HARBOURING EGFR EXON 20 INSERTION MUTATIONS ACHIEVES POSITIVE TOPLINE RESULTS irasia.com ↗ |
| 2025-06-02 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - JMT101 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF COLORECTAL CANCER irasia.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BECOTATUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650481 ↗ |
| Known as | JMT101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06380348 ↗ |
| Action | Inhibit | “anti-EGFR” NCT06735391 ↗ |
| Modality | Monoclonal antibody | “anti-EGFR monoclonal antibody” PMID 37308490 ↗ Jun 2023 |
| Route | Intravenous | “IV infusion Q2W for 4 weeks (28-day cycles)” NCT04448379 ↗ |
| Target | EGFR | “anti-EGFR monoclonal antibody” PMID 37308490 ↗ Jun 2023 |